SCHEMBL332747

SCHEMBL332747

COC1O[C@H](C)[C@H]2OC(C)(C)O[C@@H]12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7209291 1.00
SCHEMBL10041943 1.00
SCHEMBL12810045 1.00
SCHEMBL10013538 1.00
SCHEMBL10231804 1.00
SCHEMBL7214312 1.00
SCHEMBL10013536 1.00
SCHEMBL3459775 1.00
SCHEMBL26823589 0.88 LMNA (0.31)
SCHEMBL13800901 0.86 CA2 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105037453-A Preparation method of methyl-2,3-O-isopropylidene-5-deoxy-D-ribofuranoside Qidong dongyue pharmaceutical co ltd 2015-11-11 CN claimed
EP-0021231-B1 PROCESS FOR THE PREPARATION OF 5'-DEOXY-5-FLUORO URIDINE AND INTERMEDIATES IN THIS PROCESS F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1983-10-05 EP claimed
US-11220524-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2022-01-11 US disclosed
US-20210130388-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED 2021-05-06 US disclosed
CN-110483593-A A kind of preparation method of capecitabine intermediate GUIZHOU YONGNUO FEITE BIOLOGICAL PHARMACEUTICAL CO LTD 2019-11-22 CN disclosed
US-RE46144-E1 Hydroxamic acid derivatives PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2016-09-13 US disclosed
US-RE46144-E1 Hydroxamic acid derivatives PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2016-09-13 US disclosed
CN-102212095-B The preparation method of capecitabine and intermediate thereof SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2016-03-30 CN disclosed
CN-103910773-B The synthetic method of capecitabine impurity NINGBO MENOVO PHARMACEUTICAL CO., LTD. (CN) 2015-11-25 CN disclosed
CN-105037453-A Preparation method of methyl-2,3-O-isopropylidene-5-deoxy-D-ribofuranoside Qidong dongyue pharmaceutical co ltd 2015-11-11 CN disclosed
CN-105037453-A Preparation method of methyl-2,3-O-isopropylidene-5-deoxy-D-ribofuranoside Qidong dongyue pharmaceutical co ltd 2015-11-11 CN disclosed
US-20110224422-A1 PREPARATION OF CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2011-09-15 US disclosed
US-20100249395-A1 METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN HANMI PHARM. CO., LTD. (KR) 2010-09-30 US disclosed
WO-2010065586-A2 PREPARATION OF CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 WO disclosed
WO-2008117047-A1 PYRAZOLO[3, 4-D]PYRIMIDINE DERIVATIVES AS ANTIBACTERIAL COMPOUNDS ASTRAZENECA AB (SE) 2008-10-02 WO disclosed
WO-1997033590-A1 A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS NOVO NORDISK A/S (DK) 1997-09-18 WO disclosed
WO-1997033591-A1 A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS NOVO NORDISK A/S (DK) 1997-09-18 WO disclosed
EP-0602478-B1 Novel process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives HOFFMANN LA ROCHE (CH) 1996-07-31 EP disclosed
EP-0602478-A1 Novel process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 1994-06-22 EP disclosed
EP-0021231-B1 PROCESS FOR THE PREPARATION OF 5'-DEOXY-5-FLUORO URIDINE AND INTERMEDIATES IN THIS PROCESS F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1983-10-05 EP disclosed